Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Shares of Moderna Inc. gained 2.2% in premarket trading on Thursday after the company reported half a million dollars in sales of its COVID-19 vaccine in the fourth quarter of last year. The company had a loss of $272,000, or 69 cents per share, in the fourth quarter of 2020, compared with a loss of $123,000, or 37 cents per share, in the same quarter a year ago.

Moderna reports $570 million in revenue for first time driven by sales of COVID-19 vaccine

Moderna Inc said on Thursday it was expecting to post $18.4 billion in sales from its COVID-19 vaccine this year.

Moderna sees $18.4 billion in sales from COVID-19 vaccine in 2021

Axcella Health Inc

Codiak Biosciences

Denali Therapeutics

Evelo Biosciences Inc

Foghorn Therapeutics

Kaleido Biosciences Inc

Seres Therapeutics

Rubius Therapeutics Inc

Sana Biotechnology

Sigilon Therapeutics

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The round included contributions from funds...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna reports fourth quarter and fiscal year 2020 financial results and provides business updates.

Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates

Pfizer

Teladoc

Moderna, Teladoc Health, and Fulgent Genetics have all spiked a lot higher because of COVID-19. And all three companies have platforms for growth over the next decade.

3 Top Healthcare Stocks to Buy in 2021

Moderna Inc (NASDAQ: MRNA) said it was making new capital investments to increase manufacturing capacity, and next year it plans to produce 1.4 billion doses, up from an earlier estimate of 1.2 billion doses. It also raised the low end of its COVID-19 vaccine production forecast this year to 700 million doses from 600 million doses.

Moderna Raises 2021 Base COVID-19 Vaccine Production Plan To 700M Doses

Moderna Inc (NASDAQ: MRNA) is experimenting with several potential methods of combating the new COVID-19 virus strain, including: The South Africa variant-specific booster candidate at the 50 µg dose level and lower. An additional booster shot combining the South Africa-specific vaccine and its existing vaccine in a single vaccine at the 50 µg dose level and lower.

Moderna To Test New COVID-19 Vaccine Targeting South Africa Strain

BioNTech SE

Pfizer sees $15 billion revenue from the Pfizer/BioNTech COVID vaccine in 2021 and it could completely change Pfizer's revenue and earnings trajectory. Think about what this will do for BioNTech. The above revenues are for the “pandemic phase.” Pfizer/BioNTech may be considering a 3-4x price increase for their COVID-19 vaccine(s) after this phase. Read this sentence again.

COVID-19 Continues, But Good Times For mRNA Vaccine Developers Pfizer/BioNTech And Moderna

MRNA reports earnings Thursday. Revenue is expected to spike Q/Q. Revenue should remain volatile as MRNA reaches an $11 billion run rate. The stock could move on news of future supply deals. Whether MRNA's 2021 revenue is recurring is important.

Moderna: Expect Bad News Thursday

Moderna said it plans on boosting COVID-19 vaccine to 1.4 billion doses by 2022.

Moderna vows to double COVID-19 vaccine capacity by next year

Moderna said Wednesday it had manufactured a coronavirus vaccine to test against a mutation out of South Africa. The news sparked Moderna stock, which is already on a run in 2021.

Moderna Sparks On Plans To Test New Covid Vaccine Against Viral Mutant

The drugmaker is hoping to launch trials for the new booster.

Moderna Prepares Vaccine Booster Shot For South Africa Coronavirus Variant

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces it is making new capital investments to increase capacity at its owned and partnered manufacturing facilities, which it expects will increase global 2022 capacity to approximately 1.4 billion doses of its COVID-19 vaccine, assuming a 100 μg dose. The investments will enable additional production of the current Moderna COVID-19 Vaccine and

Moderna Announces Additional Capital Investments to Increase Global Manufacturing Capacity for COVID-19 Vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces that it has completed manufacturing of clinical trial material for its variant-specific vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant known as B.1.351 first identified in the Republic of South Africa, and has shipped doses to the National Institutes of Health (NIH) for a Phase 1 clinical trial that will be led and funded

Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study

New version is designed to protect against the South African variant of the virus.

Moderna Ships Updated Covid-19 Vaccine to NIH for Testing

The NIH will soon begin testing a new booster shot for Moderna's COVID-19 vaccine that could better protect people against an emerging variant, according to the biotech's chief executive.  Moderna announced Wednesday that it has shipped a new version of its vaccine to the NIH — exactly one year after it handed over its first COVID-19 vaccine candidate. A clinical trial will involve a few hundred participants and will begin "very soon," Moderna CEO Stéphane Bancel told Insider.

Moderna just laid out its booster shot strategy to fight new coronavirus variants

Moderna said it has shipped to the NIH doses of a new Covid-19 vaccine designed to provide better protection against the South Africa variant.

Moderna to begin clinical trials of Covid booster shots for variant from South Africa, sends to NIH for study

Johnson & Johnson

Pfizer Inc. (NYSE: PFE), Moderna Inc. (Nasdaq: MRNA) and Johnson & Johnson (NYSE: JNJ) said they are committed to making a total of 240 million doses of COVID-19 vaccines available in the U.S. by the end of March. What Happened: The drug makers told a House subcommittee on Tuesday they are working on ramping up production of their vaccines to meet demand.

Pfizer, Moderna, J&J Pledge To Make 240M COVID-19 Vaccine Doses Available In US By March-End

The "other" coronavirus vaccine is currently having a moment in the spotlight.

Why Moderna Stock Tanked on Tuesday

Airbnb

Etsy

NVIDIA

Block

These 5 companies were beneficiaries of the pandemic economy. But what happens next?

5 Pandemic Winner Earnings Charts

Pfizer and Moderna said Tuesday they're making improvements that will allow them to deliver more vaccines in the coming months.

Pfizer And Moderna To Dramatically Increase Covid-19 Vaccine Production This Spring

Best Buy

3D Systems

Li Auto Inc.

Plug Power

Equities took something of a beating Tuesday morning, with Home Depot down around 4% on a weak outlook and Palo Alto Networks down about 1% on a similarly dim view of the current quarter.

Earnings Previews: 3D Systems, Nvidia, Best Buy, Li Auto, Moderna, Plug Power

Eli Lilly

Regeneron Pharmaceuticals

The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.

FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs

Moderna has emerged as a strong competitor after getting authorization for a coronavirus vaccine. But Moderna stock remains on a wild ride.

News for Moderna Stock (MRNA)